Frequently Asked Questions about Spyre Therapeutics, Inc. (SYRE)

Name: Spyre Therapeutics, Inc. (SYRE) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Spyre Therapeutics, Inc. (SYRE) do?

Accepted Answer

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for t...

Question 2

Is Spyre Therapeutics, Inc. (SYRE) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of SYRE reveals an Altman Z-Score of 26.82 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if SYRE fits their risk profile.

Question 3

What is the current P/E ratio for SYRE?

Accepted Answer

As of the latest trading session, Spyre Therapeutics, Inc. (SYRE) has a trailing P/E ratio of -109.21.

Question 4

Who is the CEO of Spyre Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Spyre Therapeutics, Inc. is Cameron Turtle.

Question 5

What was SYRE's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Spyre Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.02B (2021) respectively.

Question 6

Does SYRE pay a dividend?

Accepted Answer

Spyre Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does SYRE have?

Accepted Answer

In its latest reporting period, Spyre Therapeutics, Inc. generated $-0.17B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of Spyre Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Spyre Therapeutics, Inc. (SYRE) is currently 23.70.

Question 9

What is the Price-to-Sales (P/S) ratio of SYRE?

Accepted Answer

Based on trailing twelve-month data, Spyre Therapeutics, Inc. (SYRE) trades at a Price-to-Sales (P/S) ratio of 32.69.

Question 10

What is Spyre Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Spyre Therapeutics, Inc. (SYRE) has a Return on Equity (ROE) of -29.44%, representing its profitability relative to shareholder equity.